Interestingly, LCK showed a similar pattern of upregulation in DLBCL tumor samples as BTK and SYK (Fig S5), both of which drive the BCR signaling pathway and are therapeutic targets in B-cell malignancies [25]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.